Developer docs
API playgroundTry for free, no card

Search company profiles

LabGenius

Full company profile

uuid0000dvm

Namestring
LabGenius
Legal namestring
LabGenius Limited
Websiteurl
labgeni.us
Company typeenum
Private
Founded yearint
2021
Descriptiontext

LabGenius is a UK-based, venture-backed biotechnology company that develops therapeutic antibodies using a proprietary AI-driven discovery engine called EVA. The platform combines machine learning with high-throughput automated experimentation in iterative design-build-test-learn cycles to identify and co-optimize complex antibody candidates — particularly multispecifics — across multiple properties simultaneously, a problem the company identifies as non-intuitive for conventional discovery methods. The firm maintains an internal pipeline focused on selectivity-enhanced antibodies for solid tumors, with lead asset LGTX-101, an AI-designed Nectin-4 x CD3 T-cell engager that has demonstrated greater than 90% tumor growth inhibition at 0.1 mg/kg in preclinical studies and is slated for presentation at AACR 2026. LabGenius claims its platform can compress the typical five-year antibody development timeline by approximately 50%.

The company's commercial model is a hybrid platform-plus-pipeline structure. It licenses the EVA platform to major pharmaceutical partners through multi-year research, option, and license agreements — including an ongoing collaboration with Sanofi focused on NANOBODY therapeutics for inflammation (expanded in December 2025 after a successful 2021 first collaboration) and a June 2026 agreement with LG Chem covering tumour-targeting multispecific antibodies with undisclosed upfront, early milestones, and potential triple-digit million clinical/regulatory/commercial milestones plus royalties. Revenue is generated through licensing upfronts, research funding, and contingent milestone payments; no commercial product revenue exists and pricing is not publicly disclosed. The company is headquartered in London, operates with 51-100 employees, and is backed by a syndicate including M Ventures, Atomico, Kindred Capital, Lux Capital, Obvious Ventures, Octopus Ventures, and LG Innovation Ventures, following a $44.5M financing round in May 2024.

Short descriptiontext

LabGenius is a UK-based AI biotech that uses its proprietary EVA platform, combining machine learning with automated experimentation, to discover and optimize therapeutic antibodies for solid tumors and inflammation, serving major pharmaceutical partners (Sanofi, LG Chem) via licensing and co-development while advancing an internal pipeline led by LGTX-101.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI antibody discovery, therapeutic antibody engineering, machine learning drug discovery, multispecific antibody optimization, automated protein engineering
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Platform Licensing & Research Collaborations
TypeLicensing Royalties
Description

LabGenius licenses its EVA platform to pharmaceutical companies, receiving upfront payments, research funding, and potential milestones. Deal with LG Chem includes undisclosed upfront payment, early milestones, and potential triple-digit million clinical, regulatory, and commercial milestones plus royalties on net sales.

financialcontent.com
2Collaborative Development Revenue
TypeLicensing Royalties
Description

Revenue from co-development partnerships including milestone payments tied to research, preclinical, clinical, regulatory, and commercial achievements. Sanofi collaboration focuses on antibody optimization for inflammation targets.

firstwordpharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

LabGenius operates the EVA™ platform, an AI/ML-driven discovery engine that combines machine learning with automated high-throughput experimentation in an iterative design-build-test-learn cycle to identify and co-optimise complex therapeutic antibodies across multiple properties. The company leverages this platform to develop its own internal pipeline of selectivity-enhanced antibody therapeutics for solid tumours (e.g., LGTX-101) and licenses the platform to pharmaceutical partners (Sanofi, LG Chem) for collaborative drug discovery programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Aims to reduce typical 5-year antibody development timeline by approximately 50%
+3 more records
Product overview1 text field

LabGenius is a UK-based AI biotechnology company offering a unified platform-plus-pipeline architecture. The core product is the EVA™ platform, an AI/ML-driven antibody discovery engine that combines machine learning with automated experimentation using an iterative design-build-test-learn cycle. The company leverages EVA to develop its internal pipeline of selectivity-enhanced antibody therapeutics for solid tumors, including the lead program LGTX-101, a Nectin-4 x CD3 T-cell engager. LabGenius also provides its platform as a service to pharmaceutical partners through collaborations with Sanofi and LG Chem.

Product and service2 records
1EVA™ Platform
CategoryAI Drug Discovery Platform
Description

Highly automated AI-driven discovery engine that uses machine learning combined with high-throughput experimentation in an iterative design-build-test-learn cycle to rapidly identify and co-optimise complex therapeutic antibodies across multiple key properties. Licensed to pharmaceutical partners for collaborative drug discovery and used internally to develop the company's own pipeline of selectivity-enhanced antibody therapeutics for solid tumours.

2LGTX-101
CategoryOncology Therapeutic Antibody (Pipeline)
Description

AI-designed Nectin-4 x CD3 T-cell engager for the treatment of solid tumours, demonstrating robust T-cell activation and tumour growth inhibition in preclinical studies. Part of LabGenius's internal pipeline of selectivity-enhanced antibody therapeutics.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1LG Chem
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Multi-year research collaboration, option and licensing agreement to develop AI/ML-designed tumour-targeting antibodies using LabGenius's EVA™ platform. LG Chem will fund all research and development activities. LabGenius will receive an undisclosed upfront payment and potential early milestones, with potential triple-digit million clinical, regulatory, and commercial milestones plus royalties on net sales if LG Chem exercises its option. The collaboration aims to develop next-generation multispecific antibodies targeting solid tumour antigens across multiple difficult-to-treat cancer types.

financialcontent.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Second collaboration with Sanofi for AI/ML-driven antibody optimization, focusing on NANOBODY® therapeutics for multiple inflammation targets. The partnership leverages LabGenius's EVA platform with an iterative design-build-test-learn cycle. Their previous 2021 collaboration demonstrated significant results with the 10 most enhanced NANOBODY variants achieving up to seven times the desired effect while maintaining the original molecule's potency.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public AI-driven antibody discovery company combining generative AI with high-throughput wet-lab capabilities. Most direct comparable to LabGenius in AI antibody design platform and pharma partnership model.

TypeDirect peer
Description

ML-guided antibody engineering platform with integrated wet lab for design-build-test-learn cycles. Closely overlaps with EVA's multispecific antibody optimization focus.

TypeDirect peer
Description

Generative AI biology platform developing de novo protein therapeutics across modalities including antibodies. Competes with LabGenius for pharma AI antibody partnerships and pipeline assets.

TypeDirect peer
Description

AI platform for protein design and engineering serving biologics developers. Comparable in offering ML-based protein optimization services to pharma partners.

5Antiverse
TypeDirect peer
Description

UK-based AI antibody design company focused on difficult targets including GPCRs and ion channels. Geographic peer and overlapping platform offering for antibody discovery.

TypeBroad incumbent
Description

Public antibody discovery platform with established pharma partnerships and clinical-stage pipeline. A larger, more mature incumbent operating in the same antibody discovery space.

TypeEmerging player
Description

Automated protein engineering platform using high-throughput experimentation and ML. Comparable in wet-lab automation and design-build-test-learn methodology.

TypeDirect peer
Description

UK-based antibody discovery company using proprietary technology to engineer VHH/single-domain antibodies. Direct peer in UK antibody engineering market with multispecific and NANOBODY®-adjacent capabilities.

TypeBroad incumbent
Description

Public AI-driven drug discovery platform combining high-throughput experimentation with ML. Broader scope than LabGenius (small molecules plus biologics) but operates adjacent AI/automation thesis.

TypeBroad incumbent
Description

Large-scale synthetic biology platform with cell engineering and protein capabilities. Overlaps with LabGenius in using automated biological experimentation and AI to engineer biological systems.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LabGenius

AI Drug Discoverylabgeni.us

LabGenius is a UK-based AI biotech that uses its proprietary EVA platform, combining machine learning with automated experimentation, to discover and optimize therapeutic antibodies for solid tumors and inflammation, serving major pharmaceutical partners (Sanofi, LG Chem) via licensing and co-development while advancing an internal pipeline led by LGTX-101.

What LabGenius does

LabGenius is a UK-based, venture-backed biotechnology company that develops therapeutic antibodies using a proprietary AI-driven discovery engine called EVA. The platform combines machine learning with high-throughput automated experimentation in iterative design-build-test-learn cycles to identify and co-optimize complex antibody candidates — particularly multispecifics — across multiple properties simultaneously, a problem the company identifies as non-intuitive for conventional discovery methods. The firm maintains an internal pipeline focused on selectivity-enhanced antibodies for solid tumors, with lead asset LGTX-101, an AI-designed Nectin-4 x CD3 T-cell engager that has demonstrated greater than 90% tumor growth inhibition at 0.1 mg/kg in preclinical studies and is slated for presentation at AACR 2026. LabGenius claims its platform can compress the typical five-year antibody development timeline by approximately 50%.

The company's commercial model is a hybrid platform-plus-pipeline structure. It licenses the EVA platform to major pharmaceutical partners through multi-year research, option, and license agreements — including an ongoing collaboration with Sanofi focused on NANOBODY therapeutics for inflammation (expanded in December 2025 after a successful 2021 first collaboration) and a June 2026 agreement with LG Chem covering tumour-targeting multispecific antibodies with undisclosed upfront, early milestones, and potential triple-digit million clinical/regulatory/commercial milestones plus royalties. Revenue is generated through licensing upfronts, research funding, and contingent milestone payments; no commercial product revenue exists and pricing is not publicly disclosed. The company is headquartered in London, operates with 51-100 employees, and is backed by a syndicate including M Ventures, Atomico, Kindred Capital, Lux Capital, Obvious Ventures, Octopus Ventures, and LG Innovation Ventures, following a $44.5M financing round in May 2024.

LabGenius firmographics

Firmographics
Name
LabGenius
Legal name
LabGenius Limited
Website
https://labgeni.us
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
LabGenius is a UK-based AI biotech that uses its proprietary EVA platform, combining machine learning with automated experimentation, to discover and optimize therapeutic antibodies for solid tumors and inflammation, serving major pharmaceutical partners (Sanofi, LG Chem) via licensing and co-development while advancing an internal pipeline led by LGTX-101.
Ownership category
akta.pro rank

LabGenius industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI antibody discovery
  • Therapeutic antibody engineering
  • Machine learning drug discovery
  • Multispecific antibody optimization
  • Automated protein engineering

Where LabGenius is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

LabGenius business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Licensing & Research Collaborations: LabGenius licenses its EVA platform to pharmaceutical companies, receiving upfront payments, research funding, and potential milestones. Deal with LG Chem includes undisclosed upfront payment, early milestones, and potential triple-digit million clinical, regulatory, and commercial milestones plus royalties on net sales.
  2. Collaborative Development Revenue: Revenue from co-development partnerships including milestone payments tied to research, preclinical, clinical, regulatory, and commercial achievements. Sanofi collaboration focuses on antibody optimization for inflammation targets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

LabGenius product offering

Product offering

Core offering

LabGenius operates the EVA™ platform, an AI/ML-driven discovery engine that combines machine learning with automated high-throughput experimentation in an iterative design-build-test-learn cycle to identify and co-optimise complex therapeutic antibodies across multiple properties. The company leverages this platform to develop its own internal pipeline of selectivity-enhanced antibody therapeutics for solid tumours (e.g., LGTX-101) and licenses the platform to pharmaceutical partners (Sanofi, LG Chem) for collaborative drug discovery programs.

Product overview

LabGenius is a UK-based AI biotechnology company offering a unified platform-plus-pipeline architecture. The core product is the EVA™ platform, an AI/ML-driven antibody discovery engine that combines machine learning with automated experimentation using an iterative design-build-test-learn cycle. The company leverages EVA to develop its internal pipeline of selectivity-enhanced antibody therapeutics for solid tumors, including the lead program LGTX-101, a Nectin-4 x CD3 T-cell engager. LabGenius also provides its platform as a service to pharmaceutical partners through collaborations with Sanofi and LG Chem.

Differentiator

Problem solved

Functional benefit

Products and services

  • EVA™ Platform Highly automated AI-driven discovery engine that uses machine learning combined with high-throughput experimentation in an iterative design-build-test-learn cycle to rapidly identify and co-optimise complex therapeutic antibodies across multiple key properties. Licensed to pharmaceutical partners for collaborative drug discovery and used internally to develop the company's own pipeline of selectivity-enhanced antibody therapeutics for solid tumours.
  • LGTX-101 AI-designed Nectin-4 x CD3 T-cell engager for the treatment of solid tumours, demonstrating robust T-cell activation and tumour growth inhibition in preclinical studies. Part of LabGenius's internal pipeline of selectivity-enhanced antibody therapeutics.

Quantifiable outcome

  • Aims to reduce typical 5-year antibody development timeline by approximately 50%
  • +3 more outcomes

Companies that use LabGenius

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

LabGenius technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

LabGenius partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • LG ChemcoreStrategic or Co-development Partner · 17 June 2026Multi-year research collaboration, option and licensing agreement to develop AI/ML-designed tumour-targeting antibodies using LabGenius's EVA™ platform. LG Chem will fund all research and development activities. LabGenius will receive an undisclosed upfront payment and potential early milestones, with potential triple-digit million clinical, regulatory, and commercial milestones plus royalties on net sales if LG Chem exercises its option. The collaboration aims to develop next-generation multispecific antibodies targeting solid tumour antigens across multiple difficult-to-treat cancer types.
  • SanoficoreStrategic or Co-development Partner · 4 December 2025Second collaboration with Sanofi for AI/ML-driven antibody optimization, focusing on NANOBODY® therapeutics for multiple inflammation targets. The partnership leverages LabGenius's EVA platform with an iterative design-build-test-learn cycle. Their previous 2021 collaboration demonstrated significant results with the 10 most enhanced NANOBODY variants achieving up to seven times the desired effect while maintaining the original molecule's potency.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

LabGenius competitors and assessment

Company assessment

Direct peers

  • Absci: Public AI-driven antibody discovery company combining generative AI with high-throughput wet-lab capabilities. Most direct comparable to LabGenius in AI antibody design platform and pharma partnership model.
  • BigHat Biosciences: ML-guided antibody engineering platform with integrated wet lab for design-build-test-learn cycles. Closely overlaps with EVA's multispecific antibody optimization focus.
  • Generate Biomedicines: Generative AI biology platform developing de novo protein therapeutics across modalities including antibodies. Competes with LabGenius for pharma AI antibody partnerships and pipeline assets.
  • Cradle Bio: AI platform for protein design and engineering serving biologics developers. Comparable in offering ML-based protein optimization services to pharma partners.
  • Antiverse: UK-based AI antibody design company focused on difficult targets including GPCRs and ion channels. Geographic peer and overlapping platform offering for antibody discovery.
  • Isogenica: UK-based antibody discovery company using proprietary technology to engineer VHH/single-domain antibodies. Direct peer in UK antibody engineering market with multispecific and NANOBODY®-adjacent capabilities.

Broad incumbents

  • AbCellera: Public antibody discovery platform with established pharma partnerships and clinical-stage pipeline. A larger, more mature incumbent operating in the same antibody discovery space.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery platform combining high-throughput experimentation with ML. Broader scope than LabGenius (small molecules plus biologics) but operates adjacent AI/automation thesis.
  • Ginkgo Bioworks: Large-scale synthetic biology platform with cell engineering and protein capabilities. Overlaps with LabGenius in using automated biological experimentation and AI to engineer biological systems.

Emerging players

  • Adaptyv Biosystems: Automated protein engineering platform using high-throughput experimentation and ML. Comparable in wet-lab automation and design-build-test-learn methodology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

LabGenius social profiles

Digital presence

LabGenius financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LabGenius leadership team

Management profile

Number of profiles

Profiles4 records

LabGenius funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LabGenius M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LabGenius

What does LabGenius do?

LabGenius operates the EVA™ platform, an AI/ML-driven discovery engine that combines machine learning with automated high-throughput experimentation in an iterative design-build-test-learn cycle to identify and co-optimise complex therapeutic antibodies across multiple properties. The company leverages this platform to develop its own internal pipeline of selectivity-enhanced antibody therapeutics for solid tumours (e.g., LGTX-101) and licenses the platform to pharmaceutical partners (Sanofi, LG Chem) for collaborative drug discovery programs.

Is LabGenius a public or private company?

LabGenius is a private company. It is classified as venture growth investor backed and is currently operating.

When was LabGenius founded?

LabGenius was founded in 2021. It employs 51 to 100 people.

Where is LabGenius based?

LabGenius is headquartered in London, United Kingdom, in the Europe region.

How does LabGenius make money?

Two revenue lines are on record. Platform Licensing & Research Collaborations are the primary driver. The others are collaborative Development Revenue.

Who are LabGenius's main competitors?

Direct peers on record are Absci, BigHat Biosciences, Generate Biomedicines, Cradle Bio, Antiverse and Isogenica. Broad incumbents are AbCellera, Recursion Pharmaceuticals and Ginkgo Bioworks. Adaptyv Biosystems is listed as an emerging player.

Does LabGenius have an API?

No public API is recorded for LabGenius.

What industry is LabGenius in?

LabGenius's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KBRLG Chem taps AI-powered LabGenius platform to accelerate cancer drug discoveryLG Chem has signed a joint research and license option agreement with U.K.-based LabGenius Therapeutics to discover novel multispecific antibody candidates for cancer treatment using AI. Under the deal, LG Chem will provide upfront payment and research funding while leveraging LabGenius's EVA platform, which combines machine learning with high-throughput experimentation to optimize therapeutic antibodies. The company aims to cut the typical five-year antibody development timeline roughly in half, accelerating candidates into preclinical development.FinancialContent Business PageLabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting AntibodyLabGenius Therapeutics and LG Chem have entered into a multi-year research collaboration, option and licensing agreement to develop AI/ML-designed tumour-targeting antibodies using LabGenius's EVA™ platform. LabGenius will receive an undisclosed upfront payment and potential early milestones, with potential triple-digit million clinical, regulatory, and commercial milestones plus royalties on net sales if LG Chem exercises its option. The collaboration aims to develop next-generation multispecific antibodies targeting solid tumour antigens across multiple difficult-to-treat cancer types, with LG Chem funding all research and development activities.RegmednetCell therapy weekly: new integrated platform for autologous cell therapy manufacturingSartorius launched the Eveo Cell Therapy Platform, an integrated system for autologous cell therapy manufacturing that combines raw materials, production equipment, software, and QC assays into a scalable closed system, with a pilot demonstrating nearly fourfold capacity increase and approximately 90% cost reduction. Additionally, LabGenius announced preclinical data for its Nectin-4 x CD3 T-cell engager LGTX-101 to be presented at AACR 2026, GenSight Biologics completed a €1.69 million fundraising round through Euronext Paris share issuance, and HOHCells launched FreezOpt, a patented cryovial insert for controlled ice formation during cryopreservation.Drug Target ReviewNew AI-designed T-cell engager LGTX-101 to be presented at AACR in San DiegoLabGenius Therapeutics has announced it will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at the AACR Annual Meeting 2026 in San Diego from April 17–22. In preclinical studies, LGTX-101 demonstrated robust T-cell activation at concentrations below 5 picomolar and achieved more than 90 percent tumour growth inhibition at dose levels as low as 0.1 mg/kg, with selectivity for tumour cells over healthy keratinocytes. Preliminary pharmacokinetic data suggest the antibody could support clinical dosing regimens ranging from every two to four weeks.FirstWordSanofi inks second deal with LabGenius to fine-tune AI protein designLabGenius Therapeutics announced its second collaboration with Sanofi to use AI and machine learning to optimize NANOBODY therapeutic molecules, focusing on multiple inflammation targets. The partnership will leverage LabGenius' EVA platform, which uses an iterative design-build-test-learn cycle to develop optimized protein sequences faster than traditional methods. Their previous 2021 collaboration demonstrated significant results, with the 10 most enhanced NANOBODY variants achieving up to seven times the desired effect while maintaining the original molecule's potency.LabgeniustxLabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation ProgrammesLabGenius Therapeutics announced a new collaboration with Sanofi to develop multiple AI/ML-driven antibody optimisation programmes. The deal signifies a strategic partnership aimed at leveraging advanced AI technologies in biopharmaceutical research.PharmiWeb.comLabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation ProgrammesLabGenius Therapeutics announced a second collaboration with Sanofi to use its AI/ML platform EVA™ to optimize NANOBODY® molecules for new therapeutic targets, following successful prior joint efforts. The partnership aims to enhance antibody co-optimization for treatments in inflammation. This collaboration highlights advances in AI-driven drug discovery platforms for therapeutic development.MarketScreenerLabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-Driven Antibody Optimisation ProgramsLabGenius Therapeutics announced a second collaboration with Sanofi, building on their prior partnership to apply LabGenius' AI/ML-driven EVA platform for optimizing NANOBODY molecules targeting inflammation. The collaboration will focus on co-optimizing proteins for therapeutically valuable properties across multiple new targets in the inflammation area. This expansion signals continued investment by both companies in AI-assisted drug discovery for antibody development.YahooLabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation ProgrammesLabGenius Therapeutics announced a second collaboration with Sanofi to apply its ML-driven antibody discovery platform (EVA™) to optimise NANOBODY® proteins for multiple new targets in the inflammation area. The collaboration builds on the success of their first partnership, combining LabGenius' AI/ML-driven design capabilities with Sanofi's expertise in therapeutic NANOBODY® molecules to co-optimise proteins for therapeutically valuable properties. The companies stated this partnership validates LabGenius' platform ability to tackle complex antibody co-optimisation challenges, with the goal of driving better outcomes for patients.Business Wire BlogLabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation ProgrammesLabGenius Therapeutics and Sanofi have announced a new collaboration to apply LabGenius' EVA™ machine learning platform for optimizing NANOBODY® proteins across multiple new inflammatory targets. This agreement follows the success of their previous partnership and leverages Sanofi's expertise in therapeutic molecule development alongside LabGenius' AI-driven design capabilities.